Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. DexCom, Inc.
  6. Summary
    DXCM   US2521311074

DEXCOM, INC.

(DXCM)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
541.28(c) 550.05(c) 556.54(c) 568.1(c) 566.57(c) Last
706 126 671 296 305 615 345 471 333 130 Volume
-0.59% +1.62% +1.18% +2.08% -0.27% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 400 M - -
Net income 2021 233 M - -
Net cash position 2021 523 M - -
P/E ratio 2021 241x
Yield 2021 -
Sales 2022 2 925 M - -
Net income 2022 333 M - -
Net cash position 2022 813 M - -
P/E ratio 2022 169x
Yield 2022 -
Capitalization 54 815 M 54 815 M -
EV / Sales 2021 22,6x
EV / Sales 2022 18,5x
Nbr of Employees 5 500
Free-Float 98,7%
More Financials
Company
DexCom, Inc. specialises in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals. The United States accounts for 78.3% of net sales. 
More about the company
Ratings of DexCom, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about DEXCOM, INC.
10/19INSIDER SELL : Dexcom
MT
10/18DEXCOM : Guggenheim Downgrades DexCom to Neutral from Buy
MT
10/14DEXCOM INC : Entry into a Material Definitive Agreement, Creation of a Direct Financial Ob..
AQ
10/14DexCom, Inc. Enters into A Second Amended and Restated Credit Agreement with JPMorgan C..
CI
10/13DEXCOM : Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of Peo..
BU
10/05DEXCOM SCHEDULES THIRD QUARTER 2021 : 30 p.m. Eastern Time
BU
09/29Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People..
CI
09/27INSIDER SELL : Dexcom
MT
09/17INSIDER SELL : Dexcom
MT
09/16US Stocks Mostly Lower Thursday After Surprise Retail Sales Gain, Rise in Jobless Claim..
MT
09/16US Stocks End Mostly Lower as Investors Weigh Surprise Retail Sales Gain Against Rising..
MT
09/16MIDDAY REPORT : US Stocks Drop While Yields Jump Following Mixed Economic Data
MT
09/16Equities Drop Midday While Yields Jump Following Mixed Economic Data
MT
09/16DEXCOM : Piper Sandler Raises Price Target on DexCom to $650 From $550, Maintains Overweig..
MT
09/14INSIDER SELL : Dexcom
MT
More news
News in other languages on DEXCOM, INC.
09/29DEXCOM : Le système dexcom g6 de surveillance du glucose en continu est maintenant couvert..
09/16Les actions américaines en baisse jeudi après une hausse surprise des ventes au détail ..
09/16Les actions américaines terminent en grande partie en baisse, les investisseurs évaluan..
09/16RAPPORT DE LA MI-JOURNÉE : Les actions américaines chutent et les rendements augmentent ap..
09/16Les actions chutent à la mi-journée tandis que les rendements augmentent après des donn..
More news
Analyst Recommendations on DEXCOM, INC.
More recommendations
Chart DEXCOM, INC.
Duration : Period :
DexCom, Inc. Technical Analysis Chart | DXCM | US2521311074 | MarketScreener
Technical analysis trends DEXCOM, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 566,57 $
Average target price 531,90 $
Spread / Average Target -6,12%
EPS Revisions
Managers and Directors
Kevin Ronald Sayer Chairman, President & Chief Executive Officer
Jereme M Sylvain SVP-Finance, Chief Financial & Accounting Officer
Andrew K. Balo EVP-Clinical Affairs, Regulatory Strategy
Jacob S. Leach Chief Technology Officer & Executive VP
Shelly R. Selvaraj Senior Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
DEXCOM, INC.53.24%54 815
ABBOTT LABORATORIES15.74%224 651
MEDTRONIC PLC5.08%165 656
BECTON, DICKINSON AND COMPANY-1.25%70 962
HOYA CORPORATION21.65%56 316
SARTORIUS STEDIM BIOTECH64.49%51 360